Arsenault Kaitlyn Melanie's Form 4 filing
Skye Bioscience, Inc. (SKYE) · filed Nov 19, 2024
- Accession no.
- 0001516551-24-000117
- Filed
- Nov 19, 2024
- Trade date
- Nov 15-18, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $216.7K. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001516551-25-000022 (Feb 28, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Arsenault Kaitlyn MelanieCIK 0001877242 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 15, 2024 | Common Stock | SSaleDisposed | −190 | $5.55 | −$1,054.5 | 209,548 | Direct | |
| Nov 18, 2024 | Common Stock | SSaleDisposed | −43,206 | $4.99F2 | −$215,597.94 | 166,342 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.
Referenced by the price of 1 transaction in Table I.